In recent years, with the fierce competition in the domestic market, more and more traditional Chinese medicine companies have chosen to focus on "going overseas", and have sold large varieties of Chinese patent medicines such as Angong Niuhuang Pill, Huoxiang Zhengqi Liquid, and Lianhua Qingwen overseas.
It is reported that at present, traditional Chinese medicine pharmaceutical companies, including Tongrentang, Tasly, Baiyunshan and other traditional Chinese medicine companies, are actively laying out the road of "going to sea" of Angong Niuhuang Pill. Among them, Tasly disclosed in July 2023 that the company had received a notification letter of approval for the registration of prescription drugs (traditional medicines) in Vietnam for Angong Niuhuang Pills. This means that the company has obtained a total of 10 drug approvals in Vietnam. In addition to Angong Niuhuang Pill, Tasly has been actively seeking to "go overseas" in recent years, and its products have also been approved in Vietnam, including Compound Danshen Dripping Pills, Nourishing Serum Brain Granules, and Andrographolide Dripping Pills.
Also in July 23, Yiling Pharmaceutical's Bazi Kidney Supplement Capsule, Lianhua Qingcough Tablets, Tongxinluo Capsule and Qili Qiangxin Capsule 4 innovative Chinese medicines were approved for registration in Nigeria as "herbal and natural medicines", these four proprietary Chinese medicines can not only be sold through local pharmacies, but also are expected to enter Nigerian hospitals. In June of the same year, the Pharmacy and Poisons Administration of the Ministry of Health of Kenya announced that the Chinese patent medicines Tongxinluo Capsule, Ginseng Song Yangxin Capsule and Qili Qiangxin Capsule developed and produced by Yiling Pharmaceutical Co., Ltd. have been approved for registration in Kenya, and the above three drugs can be marketed in Kenya.
In May 2023, Baiyunshan announced that its subsidiaries Zhongyi Pharmaceutical and Qixing Pharmaceutical products Sanqihua Hemorrhoidal Pill and Compound Nanban Langen Granules received the product registration certificate of the Federal Service for the Protection of Consumer Rights and Interests and Public Welfare Supervision of Russia. This also means that its two TCM products can be sold to the public in Russia, Kazakhstan, Belarus, Kyrgyzstan and Armenia.
For another example, Shanghai Hutchison Pharmaceutical's Cholening Tablets have been exported to Canada, and its Zhengqi Tablets have also obtained the Canadian marketing license on April 19, 2023, and are expected to obtain the certification of production sites outside Canada in June 2024, and the company strives to achieve export sales by the end of 2024.
Behind the high recognition of overseas markets, it is inseparable from the solid research support of traditional Chinese medicine products themselves. 2024 is a key year for the implementation of the "14th Five-Year Plan", and the industry believes that with the intensification of population aging and favorable policies to support the development of traditional Chinese medicine, in 2024, traditional Chinese medicine companies may accelerate their focus on "going overseas". The Chinese medicine sector deserves the continued attention of investors. There will also be high hopes for traditional Chinese medicine going overseas.
Bank of China** believes that the overseas product market has brought new growth opportunities to Chinese pharmaceutical companies, and at the same time, it has put forward higher requirements for pharmaceutical companies' R&D capabilities and experience.
Some analysts also pointed out that the challenge of Chinese patent medicine going overseas is still relatively large. For example, Yiling Pharmaceutical has said that there are two main constraints faced by traditional Chinese medicine going overseas: first, the problem of registration regulations, most countries do not have perfect registration regulations for traditional Chinese medicine, and there is no particularly suitable attribution category when registering Chinese patent medicines; Second, countries have different perceptions and lack of understanding of traditional Chinese medicine and Chinese herbal medicines, and many Chinese herbal medicine ingredients widely used in China are not recognized abroad, and it takes a long time to break these perceptions and restrictions.
For the future of traditional Chinese medicine going overseas, the industry still says that it is very optimistic about the prospects of traditional Chinese medicine going overseas, but the above challenges also need to be solved urgently, especially the key is the control of the quality of the source, the need to accelerate the modernization and industrialization of traditional Chinese medicine, and at the same time also need to provide service support, and enhance the understanding of overseas people about traditional Chinese medicine, and constantly promote traditional Chinese medicine to the world.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to any person.
Article**: Pharma.com.
Traditional Chinese medicine